Leucovorin use rises among autistic individuals with cerebral folate deficiency as evidence building continues

Understanding leucovorin's role in autism care

Leucovorin, a medication used to address folate metabolism differences, has seen increased prescribing among autistic individuals who have cerebral folate deficiency (CFD) - a condition where folate transport to the brain is impaired. A 2026 analysis found prescription increases correlated with improved clinician recognition of CFD biomarkers like folate receptor autoantibodies. The FDA has clarified that while leucovorin is approved for CFD treatment, this does not constitute approval for autism more broadly.

Evidence and considerations

Current research includes an ongoing clinical trial examining leucovorin's effects on language development in autistic children with CFD. Preclinical studies in zebrafish (PNAS, 2025) have identified other compounds affecting neural development, though human applicability remains unproven. A 2025 review notes challenges in developing medications targeting neurodevelopmental differences.

A 2026 analysis found prescription increases correlated with improved clinician recognition of CFD biomarkers like folate receptor autoantibodies.

Clinical decision-making

When considering leucovorin:

• CFD testing (through blood tests for folate receptor autoantibodies) should precede prescription
• Benefits and risks should be weighed with a specialist familiar with both autism and metabolic conditions
• Monitoring should track both potential benefits and side effects like digestive changes

The Autistic Self Advocacy Network emphasizes that treatment decisions should center autistic individuals' experiences and needs, distinguishing between addressing co-occurring conditions and altering core neurodivergent traits.